Common founder mutation in the LDL receptor gene causing familial hypercholesterolaemia in the Icelandic population

Haplotype analysis in 18 apparently unrelated families with familial hypercholesterolaemia (FH) in Iceland has identified at least five different chromosomes cosegregating with hypercholesterolaemia. The most common haplotype was identified in 11 of the 18 families, indicating a founder mutation res...

Full description

Saved in:

Bibliographic Details
Published in:	Human mutation 1997, Vol.10 (1), p.36-44
Main Authors:	Gudnason, Vilmundur, Sigurdsson, Gunnar, Nissen, Henrik, Humphries, Steve E.
Format:	Article
Language:	eng
Subjects:	Cells, Cultured Electrophoresis, Agar Gel familial hypercholesterolaemia Female Founder Effect Haplotypes - genetics Humans Hyperlipoproteinemia Type II - genetics Iceland Introns LDL receptor founder mutations Male Mutation Pedigree Polymorphism, Single-Stranded Conformational Receptors, LDL - genetics RNA Splicing
Online Access:	Request full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Haplotype analysis in 18 apparently unrelated families with familial hypercholesterolaemia (FH) in Iceland has identified at least five different chromosomes cosegregating with hypercholesterolaemia. The most common haplotype was identified in 11 of the 18 families, indicating a founder mutation responsible for FH in the Icelandic population. By using single‐strand conformation polymorphism (SSCP) and direct sequencing of amplified DNA, we identified a novel mutation (a T to a C) in the second nucleotide in the 5′ part of intron 4 in the LDL receptor gene. This mutation was present in ˜60% of the FH families (10/18), supporting the prediction of a common founder. These families could be traced to a common ancestor in half of the cases by going back no further than the eighteenth century. The mutation was predicted to affect correct splicing of exon 4, and analysis at the cellular level demonstrated an abnormal mRNA containing intron 4 sequence in lymphoblastoid cells from a patient carrying this mutation. Translation of the mRNA would lead to a premature stop codon and a truncated nonfunctional protein of 285 amino acids. The novel sequence change created a new restriction site for the restriction endonuclease NlaIII, and using this assay, 29 unrelated individuals with possible FH attending a lipid clinic for treatment were examined for this mutation. Two individuals in this group of patients were found to be carriers of this mutation, supporting the suggestion of a founder mutation. Using this assay for the detection of FH in the Icelandic population should identify > 60% of these individuals. Hum Mutat 10:36–44, 1997. © 1997 Wiley‐Liss, Inc.
ISSN:	1059-7794 1098-1004